首页> 美国卫生研究院文献>other >Cell Surface Self-Assembly of Hybrid Nanoconjugates via Oligonucleotide Hybridization Induces Apoptosis
【2h】

Cell Surface Self-Assembly of Hybrid Nanoconjugates via Oligonucleotide Hybridization Induces Apoptosis

机译:通过寡核苷酸杂交的杂交纳米共轭物的细胞表面自组装诱导细胞凋亡。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Hybrid nanomaterials composed of synthetic and biological building blocks possess high potential for the design of nanomedicines. The use of self-assembling nanomaterials as “bio-mimics” may trigger cellular events and result in new therapeutic effects. Motivated by this rationale, we designed a therapeutic platform that mimics the mechanism of immune effector cells to crosslink surface receptors of target cells and induce apoptosis. This platform was tested against B-cell lymphomas that highly express the surface antigen CD20. Here, two nanoconjugates were synthesized: (1) an anti-CD20 Fab’ fragment covalently linked to a single-stranded morpholino oligonucleotide (MORF1), and (2) a linear polymer of N-(2-hydroxypropyl)methacrylamide (HPMA) grafted with multiple copies of the complementary oligonucleotide MORF2. We show that the two conjugates self-assemble via MORF1-MORF2 hybridization at the surface of CD20+ malignant B-cells, which crosslinks CD20 antigens and initiates apoptosis. When tested in a murine model of human non-Hodgkin’s lymphoma, the two conjugates, either administered consecutively or as a premixture, eradicated cancer cells and produced long-term survivors. The designed therapeutics contains no small-molecule cytotoxic compounds and is immune-independent, aiming to improve over chemotherapy, radiotherapy and immunotherapy. This therapeutic platform can be applied to crosslink any non-internalizing receptor and potentially treat other diseases.
机译:由合成和生物构件组成的杂化纳米材料在纳米药物设计方面具有很高的潜力。自组装纳米材料作为“生物模拟物”的使用可能触发细胞事件并产生新的治疗效果。基于这种基本原理,我们设计了一种治疗平台,该平台模仿免疫效应细胞使目标细胞的表面受体交联并诱导凋亡的机制。该平台针对高表达表面抗原CD20的B细胞淋巴瘤进行了测试。在这里,合成了两个纳米共轭物:(1)与单链吗啉代寡核苷酸(MORF1)共价连接的抗CD20 Fab'片段,以及(2)接枝了N-(2-羟丙基)甲基丙烯酰胺(HPMA)的线性聚合物具有多个拷贝的互补寡核苷酸MORF2。我们显示这两个结合物通过在CD20 + 恶性B细胞表面进行MORF1-MORF2杂交而自组装,该细胞可交联CD20抗原并启动细胞凋亡。当在人类非霍奇金淋巴瘤的鼠模型中进行测试时,两种结合物(连续给药或以预混合物的形式给药)可消除癌细胞并产生长期存活者。设计的治疗药物不含小分子细胞毒性化合物,并且具有免疫独立性,旨在改善化学疗法,放射疗法和免疫疗法的水平。该治疗平台可用于交联任何非内在化受体并潜在地治疗其他疾病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号